公开(公告)号：US20240344114A1

公开(公告)日：2024-10-17

申请号：US18744391

申请日：2024-06-14

Applicant: Grifols Diagnostic Solutions Inc.

Inventor： Uffe Vest Schneider ,  Søren Morgenthaler Echwald ,  Nikolaj Dam Mikkelsen

IPC: C12Q1/6818

CPC classification number: C12Q1/6818

Abstract: The present invention relates to a method for detecting at least one target nucleic acid sequence from a nucleic acid mixture by a double quenched assay. The double quenched assay of the method exploits a novel approach for melting temperature mediated identification of multiple target nucleic acid sequences. The invention further relates to a kit of parts.

公开(公告)号：US20220033473A1

公开(公告)日：2022-02-03

申请号：US16479068

申请日：2019-02-15

Applicant: Grifols Diagnostic Solutions Inc.

Inventor： Elizabeth Booth ,  Virginia Montanini ,  John A. Hall ,  Jody Berry

IPC: C07K14/745 ,  C07K14/705

Abstract: Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

公开(公告)号：US20200299353A1

公开(公告)日：2020-09-24

申请号：US16321385

申请日：2018-11-29

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： JODY BERRY ,  ELIZABETH Antony BOOTH ,  JOYEE ANTONY GEORGE ,  ELISABETE NASCIMENTO ,  DANIEL NAGORE CASAS

IPC: C07K14/705 ,  G01N33/68

Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.

公开(公告)号：US20230303629A1

公开(公告)日：2023-09-28

申请号：US18020797

申请日：2021-08-17

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： EFRAIN CEH PAVIA ,  ELISABETE NASCIMENTO ,  ELIZABETH A. BOOTH ,  ZEBULON LAPOINT ,  CHARLES HOLZ ,  TRISTAN WASLEY ,  JODY MELTON WITT

IPC: C07K14/005 ,  C07K17/00 ,  C07K1/107 ,  C12N7/00

CPC classification number: C07K14/005 ,  C07K17/00 ,  C07K1/1075 ,  C12N7/00 ,  C07K2319/00 ,  C12N2770/20022 ,  C12N2770/20051

Abstract: A fusion protein includes a SARS-CoV-2 nucleocapsid N-terminal domain and/or a SARS-CoV-2 nucleocapsid C-terminal domain, wherein the fusion protein lacks the SARS-CoV-2 nucleocapsid aggregation domain.

公开(公告)号：US11746140B2

公开(公告)日：2023-09-05

申请号：US16479068

申请日：2019-02-15

Applicant: Grifols Diagnostic Solutions Inc.

Inventor： Elizabeth Booth ,  Virginia Montanini ,  John A. Hall ,  Jody Berry

IPC: C07K14/705 ,  C07K14/745

CPC classification number: C07K14/745 ,  C07K14/705 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/30

Abstract: Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

公开(公告)号：US20230220499A1

公开(公告)日：2023-07-13

申请号：US17997919

申请日：2021-05-07

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： Kui GAO ,  Anthony JAMES ,  Vanessa BRES

IPC: C12Q1/70

CPC classification number: C12Q1/701

Abstract: The medical field of COVID-19 diagnosis relates to methods for detecting SARS-CoV-2 nucleic acids in a sample as well as combinations of oligomers for determining the presence or absence of SARS-CoV-2 in a Sample.

公开(公告)号：US20210356481A1

公开(公告)日：2021-11-18

申请号：US16322870

申请日：2018-10-31

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： Quang Tran ,  JOEL WUMMER ,  DENNIS CODY

IPC: G01N35/00 ,  G01N35/02

Abstract: Systems and methods for guiding the management of blood/plasma screening laboratory workflow are disclosed. A system for analyzing biological samples can include centrifuges, pooling devices, biological sample analyzing devices, and a processor to monitor operation of the centrifuges, the pooling devices, and the biological sample analyzing devices. The processor can track the progress of the biological samples and generate progress indications In response to determining that an external control is present, the system can prevent release of the biological component to the biological sample analyzing device until the external control is also loaded into the analyzer. In response to a component of a biological sample being grouped into more than one pool or not intended to be pooled, the system can generate a warning. The system can provide a chronology of states, display the status of instruments/biological samples, indicate what components need operator attention, and search the status of samples/tests.

公开(公告)号：US20210198376A1

公开(公告)日：2021-07-01

申请号：US16079068

申请日：2018-06-01

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： VINCENZO FAVALORO ,  MATTEO BINDA ,  JOHN A. HALL ,  ELIZABETH BOOTH ,  JODY BERRY ,  PETER A. SCHWIND

IPC: C07K16/28 ,  G01N33/80

Abstract: A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.

公开(公告)号：US20240270795A1

公开(公告)日：2024-08-15

申请号：US18020870

申请日：2021-08-17

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： ELISABETE NASCIMENTO ,  ELIZABETH A. BOOTH ,  EFRAIN CEH PAVIA ,  TRISTAN WASLEY ,  ZEBULON LAPOINT ,  CHARLES HOLZ ,  ROBYN CASSAN ,  COLLEEN BROWN ,  Jody MELTON WITT

IPC: C07K14/005 ,  C12N9/72

CPC classification number: C07K14/005 ,  C12N9/6459 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/30 ,  C07K2319/50 ,  C07K2319/61 ,  C07K2319/70 ,  C12N2770/20022

Abstract: A fusion protein includes the SARS-COV-2 receptor binding domain (RBD) of the SARS-COV-2 spike protein or a fragment, and a N-terminal signal peptide, and at least one of the following: a polyhistidine tag, linker, an oligomerization tag, a region in spike protein outside RBD, a horseradish peroxidase binding domain or a protease cleavage site.

公开(公告)号：US20240209461A1

公开(公告)日：2024-06-27

申请号：US18555706

申请日：2022-04-12

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： Jeffrey M. LINNEN ,  Vanessa BRES ,  Lansha PENG ,  Lourdes PALACIOS MARTIN

IPC: C12Q1/70 ,  C12Q1/6806 ,  G01N1/10

CPC classification number: C12Q1/701 ,  C12Q1/6806 ,  G01N1/10 ,  G01N2001/1056

Abstract: Aqueous compositions are for storing a biological sample for subsequent nucleic acid testing. The compositions include a first component, which includes an anionic detergent in an amount from about 1% to 20% (w/v), a Group I metal hydroxide in an amount from about 1% to 5% (w/v), a chelating agent in an amount from about 0.5% to 5% (w/v), and a first buffer. The composition further includes a diluting component selected from water, a second buffer, a Transport Medium, Sodium Chloride (aq), and combinations. The first component can be diluted up to a maximum of about 50% (v/v) with the diluting component.